cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate†

Running Title: cGMP production of BG505 SOSIP.664 HIV-1 Env trimers

Antu K. Dey1*,# , Albert Cupo2*, Gabriel Ozorowski3, Vaneet K. Sharma1, Anna-Janina Behrens4, Eden P. Go5, Thomas J. Ketas2, Anila Yasmeen2, Per J. Klasse2, Eddy Sayeed1, Heather Desaire5, Max Crispin4, Ian A. Wilson3, Rogier W. Sanders2,6, Thomas Hassell1, Andrew Ward3, John P. Moore2,#

1 International AIDS Vaccine Initiative, 125 Broad Street, New York, NY 10004, USA
2 Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
3 Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA
4 Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK. Present address: Centre for Biological Sciences and Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK
5 Department of Chemistry, The University of Kansas, Lawrence, KA 66049, USA
6 Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

# Corresponding authors’ mailing addresses:
Antu K. Dey, International AIDS Vaccine Initiative, 125 Broad Street, New York, NY 10004, USA; Phone number 212 763 5451; Fax number 212 847 1112; email: adey@iavi.org
John P. Moore, Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA; Phone number 212 746 4462; Fax number 212 746 8340; email: jpm2003@med.cornell.edu

* A. K. Dey and A. Cupo contributed equally to this paper

†This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/bit.26498]

Additional Supporting Information may be found in the online version of this article.

This article is protected by copyright. All rights reserved
Received September 22, 2017; Revision Received October 30, 2017; Accepted November 14, 2017
Abstract

We describe the properties of BG505 SOSIP.664 HIV-1 envelope glycoprotein trimers produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are the first of a new generation of native-like trimers that are the basis for many structure-guided immunogen development programs aimed at devising how to induce broadly neutralizing antibodies (bNAbs) to HIV-1 by vaccination. The successful translation of this prototype demonstrates the feasibility of producing similar immunogens on an appropriate scale and of an acceptable quality for Phase I experimental medicine clinical trials. BG505 SOSIP.664 trimers are extensively glycosylated, contain numerous disulfide bonds and require proteolytic cleavage, all properties that pose a substantial challenge to cGMP production. Our strategy involved creating a stable CHO cell line that was adapted to serum-free culture conditions to produce envelope glycoproteins. The trimers were then purified by chromatographic methods using a 2G12 bNAb affinity column and size-exclusion chromatography. The chosen procedures allowed any adventitious viruses to be cleared from the final product to the required extent of >12 log₁₀. The final cGMP production run yielded 3.52 grams (peptidic mass) of fully purified trimers (Drug Substance) from a 200 L bioreactor, a notable yield for such a complex glycoprotein. The purified trimers were fully native-like as judged by negative-stain electron microscopy, and were stable over a multi-month period at room temperature or below and for at least one week at 50°C. Their antigenicity, disulfide bond patterns and glycan composition were consistent with trimers produced on a research laboratory scale. The methods reported here should pave the way for the cGMP production of other native-like Env glycoprotein trimers of various designs and genotypes. This article is protected by copyright. All rights reserved

Keywords: HIV-1 vaccine; native-like Env trimers; SOSIP; recombinant vaccine development; affinity purification; cGMP

This article is protected by copyright. All rights reserved
Introduction

The quest for an effective vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection continues. Various hypotheses about the nature of protective immunity are being explored using a variety of vaccine designs in animal models and human volunteers (Escolano et al., 2017; Haynes and Mascola, 2017; Korber et al., 2017; Safrit et al., 2016). One active area of research is to identify ways to induce broadly neutralizing antibodies (bNAbs) that target the envelope glycoprotein (Env) trimer on the surface of infectious HIV-1 virions (Haynes and Mascola, 2017; Sanders and Moore, 2017; Stamatatos et al., 2017). Eliciting bNAbs is an attractive concept because of their ability to counter the extensive sequence diversity that is a critical aspect of the global HIV-1 pandemic. However, despite many years of effort, no immunogen has yet been able to trigger this type of antibody response in non-human primates or humans. Although Env proteins of various designs may, in principle, contribute to the elicitation of bNAbs, much effort is now being applied to making soluble, recombinant trimers that mimic the structure of the native form of virion-associated Env (Sanders and Moore, 2017; Ward and Wilson, 2017). The first soluble trimer with appropriate in vitro properties was designated SOSIP.664, specifically one based on the BG505 clade A env gene (Sanders et al., 2015). The SOSIP.664 design includes the use of an engineered disulfide bond to covalently link and thereby stabilize the gp120 and gp41 ectodomain (gp41ECTO) subunits of the trimer, an I559P point substitution in gp41ECTO that maintains the trimer in a pre-fusion conformation, and a truncation in the C-terminal region of gp41ECTO that prevents unwanted aggregation (Sanders et al., 2013; Sanders and Moore, 2017). Co-expression of the Furin protease maximizes cleavage of the gp160 precursor protein that is required for the resulting trimer to adopt a native-like structure (Sanders and Moore, 2017; Ward and Wilson, 2017) and glycosylation (Behrens and Crispin, 2017;
The resultant soluble trimers, of BG505 and other genotypes, have a native-like structure as judged by multiple criteria including negative-stain electron microscopy (NS-EM), and they present epitopes for multiple bNAbs but few for non-neutralizing antibodies (non-NAbs) (Julien et al., 2013a; Lyumkis et al., 2013; Pancera et al., 2014; Sanders et al., 2013; Sanders and Moore, 2017; Ward and Wilson, 2017). Several stability and/or antigenicity improvements to the prototypic BG505 SOSIP.664 trimer have since been described (Chuang et al., 2017; de Taeye et al., 2015; Ringe et al., 2017b; Sanders and Moore, 2017; Torrents de la Pena et al., 2017).

When tested as immunogens in rabbits, guinea pigs and macaques, the original and improved versions of SOSIP.664 trimers of various genotypes induce a narrow-specificity neutralizing antibody (NAb) response against the autologous Tier-2 (i.e., neutralization-resistant) virus, together with NAbs to Tier-1 (i.e., neutralization-sensitive) viruses (Cheng et al., 2015; Chuang et al., 2017; de Taeye et al., 2015; Klasse et al., 2016; Sanders and Moore, 2017; Sanders et al., 2015; Torrents de la Pena et al., 2017). The latter antibodies are predominantly directed against the V3 region of gp120, and their titers can be reduced by engineering variant trimers to suppress the immunogenicity of this region (Chuang et al., 2017; de Taeye et al., 2015; Ringe et al., 2017a). Although low titers of NAbs against heterologous Tier-2 viruses are occasionally elicited, SOSIP.664 and improved trimers have not induced bNAbs in the above species (Cheng et al., 2015; Chuang et al., 2017; de Taeye et al., 2015; Klasse et al., 2016; Sanders and Moore, 2017; Sanders et al., 2015; Torrents de la Pena et al., 2017). Nonetheless, native-like trimers are key components of more sophisticated immunogen design and delivery programs aimed at eventually eliciting bNAbs (Medina-Ramirez et al., 2017; Sanders and Moore, 2017; Stamatatos et al., 2017; Ward and Wilson, 2017).
A key question in the development of any vaccine is whether the vaccine candidate can be made in practical amounts at a reasonable cost and under current Good Manufacturing Practice (cGMP) conditions that are required for use in humans. HIV-1 envelope glycoproteins of any design have not proven simple to produce as cGMP reagents, problems encountered including proteolytic damage (Wang et al., 2016; Yu et al., 2010) and aggregate formation (Finzi et al., 2010; Zambonelli et al., 2016) caused, in part, by the formation of aberrant disulfide bonds (Alam et al., 2013; Wieczorek et al., 2015; Zambonelli et al., 2016). Purification can also be problematic. These translational difficulties reflect the extensive glycosylation of HIV-1 Env, with glycans comprising half the mass, and also the presence of nine intramolecular disulfide bonds in the gp120 subunit and another in gp41 (Behrens and Crispin, 2017; Go et al., 2017; Ward and Wilson, 2017). The processing state of the glycans has proven to be particularly sensitive to the precise quaternary structure of the Env complex (Behrens and Crispin, 2017; Pritchard et al., 2015).

Monomeric gp120 subunits and oligomeric gp140 HIV-1 Env glycoproteins have been produced as cGMP-grade immunogens, but the processes are usually not straightforward and often challenging and, furthermore, these proteins do not, in any case, mimic the native structure of the virus spike (Alam et al., 2013; Behrens and Crispin, 2017; Finzi et al., 2010; Wang et al., 2016; Ward and Wilson, 2017; Wieczorek et al., 2015; Zambonelli et al., 2016). The design of SOSIP.664 trimers is, seemingly, more complex than these earlier generation glycoproteins, so it was not clear whether they could be produced in useful amounts under cGMP conditions. Here, we show that cGMP-quality BG505 SOSIP.664 trimers can indeed be made in multi-gram quantities by adapting published, research laboratory methods involving a stable Chinese Hamster Ovary (CHO) cell line and a purification strategy based around a 2G12 bNAb-affinity column (Chuang et al., 2017; Sanders et al., 2013). This purification strategy does not significantly skew
the trimer glycosylation profile (Cao et al., 2017; Pritchard et al., 2015). The resulting trimers are pure, fully native-like and highly stable for prolonged periods over a range of temperatures and incubation conditions.

**Materials and Methods**

**Production of stable CHO cell line**

A CHO cell line expressing the BG505.SOSIP.664 Env protein, together with human Furin, was constructed under contract at Catalent Pharmaceutical Solutions (CPS) using their in-house GPEx® retroviral expression system (Bleck, 2010; Bleck, 2012). CPS designed the coding DNA sequences (CDS) and PCR primers needed to assemble the Env + Furin expression cassette into the retroviral vector, via unique restriction sites flanking the CDS. A Kozak sequence was included to increase protein expression efficiency and two stop codons were added to prevent translational read-through events. The CDS for the full-length human *furin* gene was excised from the CPS in-house vector pCNS-Human Furin-WPRE GDD3276.0002. This *furin* CDS and the one for BG505 SOSIP.664 *env* were cloned by digestion of the PCR products with HindIII and XhoI, followed by ligation into the GPEx® plasmid pFCS-new MCS-WPRE-SIN and digestion with the same enzymes to allow expression from the retroviral vector. Plasmids encoding BG505 SOSIP.664 and human Furin were named pFCS-BG505SOSIP-WPRE-SIN and pFCS-Human Furin-WPRE-SIN, respectively. Each plasmid CDS was verified by sequencing.

The two retroviral expression vectors were used to create the GPEx® CHO BG505 SOSIP.664 cell line by transduction of the GPEx® CHO parental line. Two transduction rounds with the Furin vector were followed by three with the BG505 SOSIP.664 vector. The pooled cell populations were expanded for cryopreservation after each round. The final cell pool was seeded
into 96-well cell culture plates to establish clonal cell lines by the limiting dilution cloning method. The clonal lines were screened for BG505 SOSIP.664 trimer production by PGT145-ELISA (see SOM Methods). The top 20 clones, based on trimer content, were expanded and tested in duplicate 250 mL shake flask cultures. Their nutritional requirements for growth in a bioreactor were assessed in a standard fed-batch culture study, and they were then cryopreserved.

**Trimer harvest from CHO cells and purification**

Culture supernatants containing BG505 SOSIP.664 gp140 proteins were harvested at day 15, or before viability dropped below 50%, and concentrated to ~0.75 g/L (assessed by PGT145-ELISA; SOM Methods) using a 300 kDa MWCO (Molecular Weight Cut-Off) Polyethersulfone membrane. The concentrated supernatant was loaded onto a 2G12 monoclonal antibody (MAb)-resin immunoaffinity column to bind the Env proteins for 5-6 cycles (i.e., the eluate was repeatedly passed through the column). The column was made using a cGMP stock of 2G12 Mab-Toyopearl® resin purchased from Polymun Inc. (Austria) (Joos et al., 2006; Trkola et al., 2008; Trkola et al., 1996). The loaded column was washed once with phosphate-buffered saline (PBS), pH 7.4 and then with 20 mM Tris, 0.5 M NaCl, pH 8.0. Bound Env proteins were eluted using 50 mM Tris, 3 M MgCl₂, pH 7.2. The eluted fraction was concentrated using a 300 kDa MWCO Regenerated Cellulose Membrane to a target concentration of ~2 g/L and dia-filtered 6 times into 20 mM Tris, 75 mM NaCl, pH 8.0. This gp140-containing solution was treated with 0.5% Triton X-100 for 1 h at room temperature as an initial virus-inactivation step. The detergent was removed by batch absorption for 2 h with Amberlite XAD-2 (25.6 g per g of Triton X-100) followed by filtration. The clarified solution was loaded onto a ReadyToProcess MabSelect SuRe (Protein A) column to remove any 2G12 IgG that had leached from the immunoaffinity column. The flow-through fraction containing gp140 proteins was next loaded onto a mixed-mode anion exchange (MM-
AEX) Capto-adhere column. The gp140 proteins in the flow-through were passed through a Planova 20N nano-filter as a viral clearance step, concentrated via a 100 kDa MWCO Regenerated Cellulose Membrane to a target concentration of ~3 g/L, and loaded onto a Superdex 200 pg column, via 2% column volume injections. Here, the input material was divided into 6-10 aliquots for sequential size-exclusion chromatography (SEC) cycles, with the relevant trimer-fractions pooled. A final ultra-filtration/dia-filtration (UF/DF) step was performed using a 100 kDa MWCO Regenerated Cellulose membrane. The filtrate was concentrated to a trimer-content of ~3 g/L and dia-filtered 10 times into Drug Substance/Drug Product (DS/DP) buffer, i.e., 20 mM Tris, 100 mM NaCl, pH 7.5. This purified Bulk Drug Substance (BDS) was frozen and stored at -75 ± 10°C. To generate the Drug Product, the 3 g/L BDS stock solution was diluted to 2 g/L in DS/DP buffer, filtered through a 0.2 µm membrane, aliquoted into vials, frozen and stored at -75 ± 10°C.

Viral clearance study

Two ‘model’ viruses were used following the recommendation of ICH Q5A guidelines (Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin): xenotropic murine leukemia virus (XMuLV), which is a large, 70-100 nm diameter, mammalian C-type retrovirus endogenous to CHO cells, and mouse minute virus (MMV), a small, 18-24 nm diameter, non-enveloped DNA parvovirus that is resistant to heat, lipid solvent and acid pH conditions. The virus-clearance tests were carried out by deliberately adding (i.e., spiking) known amounts of a test virus to the different fractions obtained during the various production steps and demonstrating that it was successfully inactivated or removed by the subsequent steps. The tests therefore provide a measure of confidence that the same processes would also eliminate any unknown, unsuspected, harmful viruses. We monitored four purification process steps for their efficiencies at clearing the model viruses: (i) 2G12 MAb immuno-affinity column; (ii) MM-AEX
column; (iii) detergent (Triton X-100) inactivation; (iv) nano-filtration. The input material to be processed through each step was spiked with a known concentration of the test viruses and the column flow-through or eluate, or the filtrate, was collected. The amounts of the viruses present in the input and processed materials were then quantified by qPCR and/or infectivity assays to determine the extent of virus inactivation or removal, with the reduction factor expressed on a log_{10} scale.

Analytical methods

Methods for analyzing purified trimers that are substantially based on published procedures are located in the Supplementary Online Material (SOM) section.

Results

Strategy for BG505 SOSIP.664 trimer production and purification

We based our strategy for producing cGMP-quality trimers on procedures that had worked efficiently in the research laboratory to make trimers on the 1-50 mg scale (Chung et al., 2014; Sanders et al., 2013; Sanders et al., 2015). Thus, we elected to make a cell line that co-expressed the BG505 SOSIP.664 env and furin genes, and then adapted that line to growth in serum-free medium. The secreted Env proteins were passed down a 2G12-MAb immunoaffinity column, followed by the use of SEC to isolate the trimer fraction. Additional chromatographic procedures, detergent treatment and an ultrafiltration step contributed to the cGMP-required removal of adventitious, CHO cell line-derived viruses. The production of native-like trimers was monitored routinely by using an ELISA or a BLI-assay that were both based on the selectivity of the PGT145 bNAb for a quaternary, trimer-specific epitope (Chung et al., 2014; Lee et al., 2015; Sanders et al.,
The critical assay used to assess trimer quality was NS-EM imaging (Khayat et al., 2013; Sanders et al., 2013; Sanders et al., 2015). These methods are summarized in the SOM section.

Production of a stable CHO cell line and clone selection

The trimer-producing cell line was produced under contract at CPS Inc. Under research laboratory conditions, the Weill Cornell Medical College (WCMC) group had produced both 293T and CHO cell lines expressing BG505 SOSIP.664 trimers, using the Flp-In system purchased from Invitrogen and its own env + furin dual-expression vector (Chung et al., 2014). CPS has its own proprietary retroviral transduction system, GPEX®, for cell line production. As both methods were potentially suitable, and as 293T and CHO cells were each viable options for cGMP production, we minimized risk by making both 293T and CHO cell lines using both the Flp-in and GPEX® methods. Among the four cell line production attempts at CPS, the one that succeeded the quickest was the CHO cell line made using the GPEX® system; so we focused subsequent efforts on this line and did not pursue the other three options.

Production of a CHO research cell bank (RCB) at CPS involved multiple rounds of transduction of the GPEX® CHO parental cell line with a retrovector made from the two constructs developed to express the furin and BG505 SOSIP.664 env genes, followed by limiting dilution cloning (see Methods). The resulting clones were screened for native-like trimer content using the PGT145-based ELISA (SOM Methods). Thus, the clones were diluted to 2 viable cells per 200 μL of media and plated in two 96-well cell culture plates, to establish sub-clonal lines that originated from single cells. The top 24 sub-clones, as judged by trimer content, were expanded and seeded into duplicate 250 mL shake flasks for a 14-day fed-batch culture. The quantity and quality of trimers in harvested culture supernatants were assessed by PGT145-ELISA, BN-PAGE and SDS-PAGE, the latter performed with and without reducing agent for evaluation of gp120-gp41...
cleavage. The average maximum level of trimer production of the sub-clones, estimated by PGT145-ELISA, was 106 mg/L compared to 82 mg/L for the pools. A second ELISA was used to detect other forms of Env in an assay based on the F105 non-NAb against an epitope that is not exposed on native-like BG505 SOSIP.664 trimers (Sanders et al., 2013; Yasmeen et al., 2014). Taken together, a strong signal in the PGT145-ELISA combined with a low one in the F105-ELISA is a good guide to the production of native-like trimers. Various other properties of each sub-clone were also measured, specifically retroviral vector components, bioburden, mycoplasma and gene copy index. To verify the insert size, the BG505 SOSIP.664 env and the human furin sequences were checked to confirm each was present. The density of viable cells in each sub-clonal line in the fed-batch shake flasks was also measured. Each sub-clonal line was cryopreserved for later viability testing. The above test results were used to select the four best performing sub-clones (232-4, 270-4, 327-9, 397-3) for the RCB. Their key properties (estimated trimer yield, cell viability during growth and post-thaw, gene copy index and insert verification) are summarized in Table 1.

From the RCB, sub-clone 270-4 was chosen for further process development and to establish a master cell bank (MCB). We first conducted an MCB stability study to assess whether this sub-clone was suitably stable in respect of its viability, growth rate and secretion of native-like (i.e., PGT145-reactive) trimers during long-term culture. To do so, the 270-4 sub-clone was thawed from the MCB and continuously cultured by serial passage for 42 generations in shake flasks using CD OptiCHO medium supplemented with 6 mM L-glutamine. Cell samples were frozen at generations 0, 4, 8, 12, 17, 22, 28, 35 and 42 for later analysis. At that time, the cells from generations 0, 8, 17, 28, 35 and 42 were thawed and cultured, with the outcomes summarized in Table 2. Trimer expression, as measured using PGT145-ELISA, varied from 85 ± 1 to 101 ± 20
mg/L among the 6 test samples, and the expression levels at the start (generation-0) and end (generation-42) were highly comparable. To assess the stability of the gene inserts, DNA was isolated from the same 6 samples and the copy number measured by real-time PCR. It ranged from 5.55 to 5.94 gene copies per cell over the course of the experiment, which is a non-significant variation based on overlapping standard deviations among the individual values. Viability was also comparable for all the samples (Table 2).

We concluded that sub-clone 270-4, which was the MCB for the BG505 SOSIP.664 trimer-producing CHO cell line, is genetically stable, retains high cellular viability and sustains its production of native-like trimers over 42 generations. These properties drove the decision to proceed with the MCB for product development.

**Upstream process development to produce Env proteins from the stable GPEX® CHO MCB**

We chose to have the GPEX® CHO MCB (sub-clone 270-4) transferred to KBI Biopharma Inc. (KBI) for upstream process development and the production of Env proteins. To develop a cell culture process, we first carried out a feed-screening study in shake flasks on a 1 L scale and several studies in a 3 L bioreactor to identify the optimal feeds, feeding strategy and temperature shift conditions (e.g., whether a shift from 37°C to a lower temperature, such as 32°C or 34°C, could improve Env protein production). A seed train optimization study in shake flasks led to the choice of CD OptiCHO medium supplemented with 6 mM L-glutamine and 0.25 g/L Cell Boost 4. The various small-scale 1 L and 3 L culture studies established the key process parameters for larger scale production runs. The upstream and downstream processes were then evaluated and "locked" by performing a 50 L Confirmation Run, using a single vial from the MCB. After the successful completion of this run, the scalability of the process was evaluated by performing a 200 L Demonstration Run involving the use of a MCB-derived seed train in an XDR 200 L single-
use bioreactor (SUB) (Fig. S1, Table S1). The goal was to assess whether the optimized process could eventually be applied to a cGMP Run on a 200 L scale. The same media and supplements were used for the Wave (50 L) and production bioreactors (200 L), except that the anti-foaming agent 0.1% Poloxamer 188 was added to the bioreactor. The Demonstration Run produced 184 L of clarified harvest supernatant containing ~21 grams of unpurified BG505 SOSIP.664 trimer (i.e., 114 mg/L), as estimated in the PGT145-BLI assay (see SOM Methods).

Purification of native-like BG505 SOSIP.664 trimers

The trimer-purification strategy was based around one that had been used successfully at the research laboratory level, i.e., immuno-affinity extraction of Env proteins from culture supernatants using a 2G12 bNAb-Toyopearl® resin column, followed by SEC to purify the trimer fraction (Chung et al., 2014; Sanders et al., 2013; Sanders et al., 2015) (Fig. 1). However, additional steps were incorporated into the cGMP process. A Protein A column (ReadyToProcess MabSelect SuRe) captured any 2G12 IgG that had leached from the affinity column, and an MM-AEX Capto Adhere column to remove host-cell protein and other process impurities before the SEC stage. The four column runs each contribute to the overall viral clearance/inactivation process, but two additional dedicated steps were also involved: Detergent (Triton X-100) inactivation and viral nano-filtration (Planova 20N membrane).

Briefly, culture supernatant was harvested on day 15 or before cell viability dropped below 50%, concentrated and loaded onto a 2G12 MAb-resin immunoaffinity column to allow capture of the BG505 SOSIP.664 gp140 proteins. After washing the column, the captured proteins were eluted using a neutral-buffered solution of 3 M MgCl₂, and the eluted fraction was rapidly diluted 7-fold in 20mM Tris, 75mM NaCl, pH 8 and then further buffer-exchanged and concentrated through UF/DF into the same buffer. The resulting solution was treated with Triton X-100
detergent as a virus-inactivation step, the detergent was removed using Amberlite resin and the processed material passed down a Protein A column to trap any 2G12 MAb that may have leached from the immunoaffinity column. Non-Env contaminants (e.g., host cell proteins) were then removed by passage down an MM-AEX column. The gp140 proteins present in the eluate were then passed through the Planova nanofiltration system, another virus-removal step, concentrated and then fractionated on a SEC column to isolate the trimers. The pooled trimer fractions were then filtered once more, this time in a UF/DF system, concentrated to ~3 g/L and buffer-exchanged via DF into the DS/DP buffer.

The robustness and effectiveness of the purification process was assessed by analyzing the Drug Substance products derived from the 50 L Confirmation Run, the 200 L Demonstration Run and the final 200 L cGMP Run (Table 3). In each case, the outcome was that >95% of the purified Env proteins were trimeric as determined by SEC, and >90% were PGT145-reactive trimers as determined by PGT145-BLI (Table 3). The purity of the trimers (i.e., the absence of other protein contaminants) was ≥ 90%, as determined by RP-HPLC. We also verified that all process-related contaminants (host cell protein, DNA, 2G12, Protein A) were present at levels that were either very low or below the Limit of Quantitation (LOQ) (Table 3). NS-EM imaging showed that 100% of the trimers from all three of the production runs were in native-like conformations (Fig. 2). Thus, we purified 3.52 grams of native-like BG505 SOSIP.664 trimers using the chosen procedures, of which 1.8 grams were used for filling the Drug Product vials. The rest was used for Drug Substance stability testing, stored as “retains” in satellite containers (for future testing, if required) or assigned to bio-burden and other release testing studies.
Viral clearance/inactivation

There is an inherent risk that any biotechnology product derived from a cell line could be contaminated by adventitious viruses present in the cell line itself (here, the CHO cells) or accidentally introduced during the production process. Because of the true or perceived risk to humans, regulatory agencies such as the Food and Drug Administration (FDA) require the use of a testing program to assess the inactivation or removal of viruses and thereby demonstrate that the resulting product meets recommended safety guidelines.

There are three main approaches to controlling potential viral contamination: (i) Selecting cell lines and other raw materials, including cell culture components, proven to be free of contaminating viruses that may be infectious in humans; (ii) testing the product during the production process to verify that no virus contamination has occurred; (iii) assessing the capacity of the production (i.e., the purification) processes to chemically inactivate or physically remove infectious viruses. Accordingly, we used FDA-recommended procedures to test the CHO cell substrate, including the MCB, and relevant raw materials for viral contaminants. Since no viruses, virus-like particles, or retrovirus-like particles, were found in the cell substrate or other raw materials, we followed regulatory guidelines and assessed the capacity of the production process to clear ‘spiked’ infectious model viruses. The objective of this viral clearance study was to identify steps in the BG505 SOSIP.664 trimer purification process that are expected to be effective in inactivating/removing viruses. These steps were then challenged by the addition of known amounts of spiked viruses to allow us to quantify the extent of virus load reduction achieved in each individual step, and overall. This information was used to estimate the risk of virus contamination in the final dosage form of the trimer product.
The overall purification process successfully removed/inactivated the model adventitious viruses by $>12 \log_{10}$, which is the minimum reduction required by regulatory guidelines using theoretical calculations based on the likely clinical dose of the BG505 SOSIP.664 trimers. The two dedicated viral clearance/inactivation steps based on non-ionic detergent (Triton X-100) and nanofiltration (Planova 20N) contributed substantially to viral inactivation and removal, respectively (Fig. 1). Thus, Triton X-100 treatment inactivated the spiked input XuMLV by 5.96 log$_{10}$. Since Triton X-100 is known to not inactivate the non-enveloped MMV, we did not assess its effect on this virus. Filtration via the Planova 20N filter successfully removed both XMuLV and MMV by $>5 \log_{10}$ (Table 4). The 2G12 MAb immuno-affinity and MM-AEX column steps also contributed to viral clearance. The 2G12 column was particularly successful at removing the large XMuLV viruses ($>5 \log_{10}$) and also helped with the smaller MMV, although to a much lesser extent ($\sim1 \log_{10}$). The MM-AEX column run was highly effective in both cases, achieving reductions of $>4 \log_{10}$ for XMuLV and $>6 \log_{10}$ for MMV (Table 4). Cumulatively, these various individual steps achieved the required $13 \log_{10}$ viral load reductions and without compromising the quality of the resulting trimers (Fig. 2, Table 3, Table 4).

Characterization of purified BG505 SOSIP.664 trimers

Purified trimers from the Demonstration Run were studied in multiple assays to assess their quality and properties (Fig. 2, Table 3, Fig. S2). Env gp140 purity (i.e., absence of non-Env contaminants), and trimer purity (i.e., absence of non-trimeric forms of Env) properties were assessed by a variety of biochemical methods including SE-HPLC, NS-EM, PGT145-BLI and RP-HPLC (see SOM Methods). Trimer purity was estimated to be $\geq 96\%$ using SE-HPLC. In addition, NS-EM imaging showed that 100% of the visible Env proteins had native-like trimer conformations (Fig. 2). A comparison of reducing and non-reducing SDS-PAGE gels confirmed
that the purified trimers were fully cleaved (to the limit of detection) between the gp120 and gp140\textsubscript{ECTO} subunits (Fig. S2). This finding is consistent with the NS-EM images. Hence, the Furin co-expression method to maximize cleavage clearly works under scaled-up production conditions.

The same gels show that, as expected, the trimers were not proteolytically clipped in the gp120 V3 region or elsewhere (Fig. S2). That particular problem commonly arises when monomeric gp120 proteins and some uncleaved gp140s are scaled up (Alam et al., 2013; Wang et al., 2016; Wieczorek et al., 2015; Zambonelli et al., 2016). Similarly, the trimers did not form aggregates, either via hydrophobic interactions or through the formation of aberrant inter-molecular disulfide bonds, which is another frequently observed problem when uncleaved gp140s and some gp120s are produced on a large scale (Coutu and Finzi, 2015; Finzi et al., 2010; Go et al., 2015; Go et al., 2014; Go et al., 2011; Ringe et al., 2015; Wang et al., 2016; Wieczorek et al., 2015; Zambonelli et al., 2016).

DSC was used to analyze the thermal stability of the trimers. The spectrum showed a sharp thermal transition with an onset of unfolding at 59.4°C and a melting temperature of 66.6°C, consistent with an earlier report (Sanders et al., 2013) (Fig. 3A).

In a sialic acid content analysis, the molar ratio of Neu5Gc to BG505 SOSIP.664 was below the limit of quantitation (LOQ) of the assay (< 0.011 mol/mol), while the corresponding molar ratio for Neu5Ac was 0.3 mol/mol. These findings are consistent with the UPLC analysis of enzymatically-released glycans, which showed a minimal sialic acid content (Fig. 4). The undetectable Neu5Gc content suggests that this component of the trimers would not be immunogenic in humans.

Aberrant intra-molecular disulfide bonds are commonly found in monomeric gp120 and uncleaved gp140 proteins (Alam et al., 2013; Coutu and Finzi, 2015; Finzi et al., 2010; Go et al.,
These events create non-native sub-populations on which relevant epitopes are not properly presented (Coutu and Finzi, 2015; Go et al., 2015; Ringe et al., 2015; Zambonelli et al., 2016). The disulfide bond profile of the purified trimers, as determined by mass spectrometry (MS), closely replicated the canonical profile of a research grade stock of this protein (Go et al., 2015). All of the native (canonical) disulfide bonded peptides were detected in high abundance (Table S3A). Two low-abundant non-canonical peptides were found at < 5% abundance, i.e., in trace amounts (Table S3B). These same peptides were also detected at < 5% abundance when analyzing the research grade preparation of BG505 SOSIP.664 trimers (Go et al., 2015). Hence, the scaled-up production process yielded a near-homogenous population of trimers with the appropriate disulfide bond profile.

The free thiol group concentration of the trimers, as measured spectrophotometrically after treatment with Ellman’s reagent, was below the LOQ of the assay (3.125 µM), and is therefore <0.7 mol of free thiol per mol of trimer. Free thiol groups were also sought in the MS data set but none was found. The estimated abundance of unpaired Cys in the trimers is < 1%.

The glycan composition of the purified trimers showed that the gp120 component was dominated by the oligomannose-type glycans, Man$_9$GlcNc$_2$ (M9) and Man$_8$GlcNAc$_2$ (M8), as found for the research grade stock of the same trimers, and that is considered to be a hallmark of a native-like trimer conformation (Fig. 4) (Behrens and Crispin, 2017; Behrens et al., 2016; Go et al., 2017; Pritchard et al., 2015). The site specific glycosylation also closely matched that reported for similarly analyzed research grade material (Fig. 4D) (Behrens and Crispin, 2017; Behrens et al., 2016). Again, there are no indications that producing the BG505 SOSIP.664 trimers in much larger quantities in a stable CHO cell line decreases their quality.
In an SPR analysis, when the purified trimers were flowed over chip-bound 3BNC117, 2G12, PGT130, PG9, PGT145, PGT151, 35O22 or 3BC315, the resulting binding profiles confirmed that the epitopes for all of these bNAbs were present (Fig. 5).

**Formulation development**

Two central elements of vaccine formulation development are that key physicochemical and functional qualities of the immunogen remain stable, and that the immunogen can be formulated for safe administration to human volunteers. To determine the optimal storage condition at -75 ± 10°C, we performed a series of experiments in which we assessed the stability of purified BG505 SOSIP.664 trimers in a range of buffers, at different pH values, and with or without excipients. An initial Buffer Screening study tested the trimers at 2 mg/mL in 3 buffers, at -75 ± 10°C, at a range of pH values, and with and without 100 mM NaCl. The specific buffers were: 10 mM sodium citrate ± 100 mM NaCl at pH 5.0, 6.0 and 7.0; 20 mM sodium phosphate ± 100 mM NaCl at pH 6.5, 7.5 and 8.0; and 20 mM Tris ± 100 mM NaCl at pH 7.5, 8.0 and 8.5. When the formulated samples were analyzed using visual appearance, A280 (protein concentration), buffer pH, DSC (thermal stability), SEC (trimer size) and DLS (protein particle size homogeneity) endpoints (see SOM Methods), none of the buffer conditions was found to affect any measured parameter. A second Excipient Screening study was then conducted in which the trimers (2 mg/mL) were incubated for 1 week at 25 ± 2°C and 60 ± 5% relative humidity. The test buffers each contained 100 mM NaCl over a narrower pH range close to their pKa values, specifically 10 mM sodium citrate (pKa 6.4) at pH 6.5 and 7.0; 20 mM sodium phosphate (pKa 7.2) at pH 7.5 and 8.0; 20 mM Tris (pKa 8.1) at pH 7.5. Each buffer was tested with and without 150 mM L-arginine or 250 mM sucrose to see whether either excipient conferred a stability increase (Table S4). As a control, additional trimer samples were incubated in the same buffers at
5 ± 3°C, with no added excipient. Based on the above endpoints, we observed no change to the properties of the trimers during the 1-week incubation, irrespective of whether either arginine or sucrose was added as a potentially stabilizing excipient.

We then conducted an Accelerated Stability study in which a PGT145-BLI endpoint was added to identify any changes in trimer conformation during prolonged storage. Trimers (2 mg/mL) were incubated for up to 4 weeks in 20 mM Tris, 100 mM NaCl at pH 7.5 with or without 250 mM sucrose at 5 ± 3°C, -20 ± 5°C or -75 ± 10°C, and then assessed using the above endpoints of visual appearance, A280, pH, SEC, DLS and PGT145-BLI. No changes to the trimers were observed after the 4-week incubation with no identifiable benefit of adding sucrose. In the final bulk freeze-thaw study, the trimers were formulated at a higher concentration of 10 mg/mL in 20 mM Tris, 100 mM NaCl, pH 7.5 with and without sucrose, and then processed through five freeze-thaw cycles between -75 ± 10°C and room temperature. The five cycles had no detectable effect on any endpoint, irrespective of the presence of sucrose. Accordingly, DS/DP (20 mM Tris, 100 mM NaCl, pH 7.5) was selected as the final formulation buffer for BG505 SOSIP.664 trimers.

**Forced Degradation study**

This study was intended to identify BG505 SOSIP.664 trimer degradation pathways and products (see SOM for details). The purified trimers were stable under all test conditions except when oxidized with 0.04% H2O2 or when exposed to a low pH (3.5) solution (Table 5).

**Discussion**

Here, we describe the successful production of multi-gram amounts of cGMP-quality, BG505 SOSIP.664 trimers from a stable CHO cell line. An initial 50 L (small-scale) run was followed by a 200 L non-cGMP Demonstration Run and finally by a 200 L cGMP run. In each of the runs, the quality of the purified trimers was at least as high as those produced on a laboratory
scale, but yields from the optimized process were ~2-fold greater (Chung et al., 2014; Sanders et al., 2013). Taking into account that the scale-up involves a 10-step purification process, as opposed to a 2-step one, the cGMP process overall was demonstrably efficient. The resulting cGMP-grade trimers are highly pure and fully native-like when assessed by NS-EM, have the high oligomannose glycan content that is now considered a hallmark of native Env proteins, are not proteolytically clipped, have the expected, canonical disulfide bond profile, and display conformationally sensitive bNAb epitopes. In all respects, the cGMP-quality trimers closely resemble those produced in research laboratories on a much smaller scale. Clearly, the basic procedures developed in the research laboratory were capable of successful scale-up without compromising the properties of the end product. The final cGMP production run yield of 3.52 grams of purified trimer represents a 58.4% recovery in the overall downstream purification process. That recovery is significantly higher than for previously manufactured HIV-1 Env clinical trial candidates, and may be attributable to the efficiency of the mAb-based affinity capture step. However, due to cGMP testing and stability requirements, only 1.8 grams were used to prepare Drug Product vials containing 0.55 mL of a 2-mg/mL trimer stock (i.e., 1.1 mg per vial). Note that the amount of trimers recorded is based on the peptidic content. The actual mass, accounting for the glycans, is ~1.7-fold higher. The optimal dose of appropriately adjuvanted trimers for human use, based on experiences in rhesus macaques, is likely to be in the range 100-300 µg, with at least three doses required to elicit an autologous NAb response.

When we contemplated starting this translational project, we were far from sure that it could be completed successfully. Many large-scale HIV-1 Env protein production programs have not proceeded smoothly and we were aware that the seeming complexity of SOSIP trimers, combined with the necessity for Furin co-expression, could present additional challenges. In
addition, we intended to use a purification strategy based on a bNAb affinity column. To our knowledge, this technique had never previously been reported for large-scale, cGMP production of an Env protein. In practice, we encountered no serious obstacles that caused substantive delays. Taken into account only the time for “wet work”, the period between the initiating cell line production and the purification of the cGMP-grade trimers, was only 24 months, far shorter than we expected based on general experiences gleaned from the Env vaccine field (n.b., the time taken to put in place legal agreements, including for the transfer of the CHO cell line from one contractor to another, added more than 6-8 months to the overall duration of the project).

There are several reasons for this rapid progress. A considerable amount of research had already established key procedures, including demonstrating that fully cleaved and native-like BG505 SOSIP.664 trimers could be produced from Env + Furin co-expressing 293T or CHO cell lines (Chung et al., 2014); showing that a 2G12 affinity column was a highly efficient way to start the trimer purification process combined with the knowledge that a cGMP-grade stock of this bNAb already existed (Joos et al., 2006; Sanders et al., 2013; Trkola et al., 2008; Trkola et al., 1996); and assessing which virus-inactivation procedures might be feasible for use in a cGMP production process. It was also prudent to evaluate four different ways to make a cGMP-quality stable cell line. In this project, the one chosen was a CHO cell line made via the Catalent in-house GPEx® system. We note, however, that we have since made four different SOSIP trimer-expressing CHO cell lines successfully in a cGMP suite at the WCMC, via the same Flp-in system used to produce multiple lines under standard laboratory conditions (Chung et al., 2014; Pugach et al., 2015; Ringe et al., 2017b).

The above points notwithstanding, we judge that the principal reason for the rapid progress of this project is that the BG505 SOSIP.664 trimer was much simpler to produce on a relevant
scale than earlier forms of Env, not harder. Because of how they fold into a compact, native-like structure, SOSIP trimers are not vulnerable to proteolytic clipping (and any V3-clipping for more sensitive clade B trimers can be eliminated by a point substitution) (Pugach et al., 2015). They are also not subject to the disulfide bond scrambling that creates improperly folded proteins, including disulfide-linked aggregates (Go et al., 2015). The absence of surface exposed hydrophobic patches also reduces or even eliminates aggregate formation (Khayat et al., 2013; Klasse et al., 2013). All of these problems arise with gp120 monomers and uncleaved gp140s during production on a laboratory scale or greater (Alam et al., 2013; Coutu and Finzi, 2015; Finzi et al., 2010; Go et al., 2015; Go et al., 2014; Go et al., 2011; Ringe et al., 2015; Wang et al., 2016; Wieczorek et al., 2015; Yu et al., 2010; Zambonelli et al., 2016). The Forced Degradation study confirmed that the purified BG505 SOSIP.664 trimers were highly stable for prolonged periods, even at elevated temperatures. Only exposure to an acidic pH of 3.5 caused the trimers to disintegrate catastrophically into monomers and dimers, as judged by several techniques including NS-EM, PGT145-BLI and SE-HPLC. Oxidation caused by H2O2 damaged the trimers in a way that affected the PGT145 epitope and affected how the (oxidized) trimers migrated on RP-HPLC. These various methods can, therefore, be used to monitor the stability of purified trimers during stability studies, in general.

The success of this translational project provides a template for ongoing or future projects aimed at producing large amounts of native-like trimers of follow-on designs. The procedures established here should be adaptable for many other trimers, provided that they are well designed and provably stable in laboratory-based studies. One variable may be the identity of the bNAb chosen for purification. BG505 and several other genotypes of SOSIP trimer can be successfully purified using 2G12, but some cannot due to contamination by a subset of non-native pseudo-
trimers that are not removed by an SEC column (Ringe et al., 2015). Other chromatographic procedures may be helpful here (Verkerke et al., 2016). However, our preferred option is to use a conformationally selective bNAb such as PGT145 to positively select only the native-like trimer population (de Taeye et al., 2015; Pugach et al., 2015; Ringe et al., 2015). Anticipating that such a method might be useful, we suggested that PG145 should be produced as a cGMP-grade reagent for trimer affinity purification. Programs to accomplish this goal are now under way in the USA and Europe. Several other bNAbs that are now being produced as cGMP-grade reagents for clinical trials of passive antibody therapies in HIV-1 infected people could also be evaluated for trimer purification (Escolano et al., 2017; Pancera et al., 2014).

Animal model research may eventually identify a moderate number of SOSIP trimers that, if used in combination, simultaneously or more likely sequentially, could induce bNAbs in humans. If so, we have now established that there is a reasonable probability that they could be produced under cGMP conditions in appropriate quantities without compromising their quality.

Acknowledgments

This cGMP manufacturing work was supported by the Bill & Melinda Gates Foundation [OPP1153692]. Grants OPP1132237 and OPP1115782 from the Bill and Melinda Gates Foundation (BMGF) Collaboration for AIDS Vaccine Development, and P01 AI110657 from NIH supported this research. NIH award UM1AI100663 to the Scripps CHAVI-ID helped to fund the production of the CHO cell RCB; we thank Salvatore Butera of that group for advice during this stage of the project. The Process Development and cGMP manufacturing of BG505 SOSIP.664 at CPS and KBP was funded by BMGF through the VxPDC core (OPP1153692) and manufacturing (OPP1147661) grants to IAVI. We thank the Catalent Pharmaceutical Solutions and KBI Biopharma Inc. project teams for their skilled efforts in CHO cell line development and in process
development and cGMP manufacturing, respectively. We appreciate the oversight provided by Sam Pallerla (IAVI) during the cGMP manufacturing process at KBI Biopharma. We are particularly grateful to Jim Bradac (NIH) and Pervin Anklesaria (BMGF) for their consistently high quality input and support that were instrumental to the outcome of this translational program.

**Conflict of interest disclosure**

JPM, RWS, IAW and ABW are listed on a patent filed by IAVI regarding BG505 SOSIP.664 trimers.
References:
Alam, S.M., H.X. Liao, G.D. Tomaras, M. Bonsignori, C.Y. Tsao, K.K. Hwang, H. Chen, K.E. Lloyd, C. Bowman, L. Sutherland, T.L. Jeffries, Jr., D.M. Koizink, S. Stewart, K. Anasti, F.H. Jaeger, R. Parks, N.L. Yates, R.G. Overman, F. Sinangil, P.W. Berman, P. Pitisutithum, J. Kaewkungwal, S. Nitayaphan, N. Karasavva, S. Rerks-Ngarm, J.H. Kim, N.L. Michael, S. Zolla-Pazner, S. Santra, N.L. Letvin, S.C. Harrison, and B.F. Haynes. 2013. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. *J Virol* 87:1554-1568.

Behrens, A.J., and M. Crispin. 2017. Structural principles controlling HIV envelope glycosylation. *Curr Opin Struct Biol* 44:125-133.

Behrens, A.J., S. Vasiljevic, L.K. Pritchard, D.J. Harvey, R.S. Andev, S.A. Krumm, W.B. Struwe, A. Cupo, A. Kumar, N. Zitzmann, G.E. Seabright, H.B. Kramer, D.I. Spencer, L. Royle, J.H. Lee, P.J. Klasse, D.R. Burton, I.A. Wilson, A.B. Ward, R.W. Sanders, J.P. Moore, K.J. Doores, and M. Crispin. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 Envelope glycoprotein. *Cell Rep* 14:2695-2706.

Blattner, C., J.H. Lee, K. Sliepen, R. Derking, E. Falkowska, A.T. de la Pena, A. Cupo, J.P. Julien, M. van Gils, P.S. Lee, W. Peng, J.C. Paulson, P. Poignard, D.R. Burton, J.P. Moore, R.W. Sanders, I.A. Wilson, and A.B. Ward. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. *Immunity* 40:669-680.

Bleck, G.T. 2010. GPEX® A flexible method for the rapid generation of stable, high expressing, antibody producing mammalian cell lines. American Association of Pharmaceutical Scientists, 12 pp.

Bleck, G.T. 2012. Consistent Production of genetically stable mammalian cell lines. *BioPharm International* 25:56-59.

Cao, L., J.K. Diedrich, D.W. Kulp, M. Pauthner, L. He, S.R. Park, D. Sok, C.Y. Su, C.M. Delahunty, S. Menis, R. Andrabi, J. Guenaga, E. Georgeson, M. Kubitz, Y. Adachi, D.R. Burton,
W.R. Schief, J.R. Yates III, and J.C. Paulson. 2017. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. *Nat Commun* 8:14954.

Cheng, C., M. Pancera, A. Bossert, S.D. Schmidt, R.E. Chen, X. Chen, A. Druz, S. Narpala, N.A. Doria-Rose, A.B. McDermott, P.D. Kwong, and J.R. Mascola. 2015. Immunogenicity of a prefusion HIV-1 Envelope trimer in complex with a quaternary-structure-specific antibody. *J Virol* 90:2740-2755.

Chuang, G.Y., H. Geng, M. Pancera, K. Xu, C. Cheng, P. Acharya, M. Chambers, A. Druz, Y. Tsybovsky, T.G. Wanningre, Y. Yang, N.A. Doria-Rose, I.S. Georgiev, J. Gorman, M.G. Joyce, S. O'Dell, T. Zhou, A.B. McDermott, J.R. Mascola, and P.D. Kwong. 2017. Structure-based design of a soluble prefusion-closed HIV-1 Env trimer with reduced CD4 affinity and improved immunogenicity. *J Virol* 91:

Chung, N.P., K. Matthews, H.J. Kim, T.J. Ketas, M. Golabek, K. de Los Reyes, J. Korzun, A. Yasmeen, R.W. Sanders, P.J. Klasse, I.A. Wilson, A.B. Ward, A.J. Marozsan, J.P. Moore, and A. Cupo. 2014. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. *Retrovirology* 11:33.

Coutu, M., and A. Finzi. 2015. HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. *J Virol Methods* 215-216:37-44.

de Taeye, S.W., G. Ozorowski, A. Torrents de la Pena, M. Guttman, J.P. Julien, T.L. van den Kerkhof, J.A. Burger, L.K. Pritchard, P. Pugach, A. Yasmeen, J. Crampton, J. Hu, I. Bontjer, J.L. Torres, H. Arendt, J. DeStefano, W.C. Koff, H. Schuitemaker, D. Eggink, B. Berkhout, H. Dean, C. LaBranche, S. Crotty, M. Crispin, D.C. Montefiori, P.J. Klasse, K.K. Lee, J.P. Moore, I.A. Wilson, A.B. Ward, and R.W. Sanders. 2015. Immunogenicity of stabilized HIV-1 Envelope trimers with reduced exposure of non-neutralizing epitopes. *Cell* 163:1702-1715.

Escolano, A., P. Dosenovic, and M.C. Nussenzweig. 2017. Progress toward active or passive HIV-1 vaccination. *J Exp Med* 214:3-16.
Finzi, A., B. Pacheco, X. Zeng, Y.D. Kwon, P.D. Kwong, and J. Sodroski. 2010. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. *J Virol Methods* 168:155-161.

Go, E.P., A. Cupo, R. Ringe, P. Pugach, J.P. Moore, and H. Desaire. 2015. Native conformation and canonical disulfide bond formation are interlinked properties of HIV-1 Env glycoproteins. *J Virol* 90:2884-2894.

Go, E.P., H. Ding, S. Zhang, R.P. Ringe, N. Nicely, D. Hua, R.T. Steinbock, M. Golabek, J. Alin, S.M. Alam, A. Cupo, B.F. Haynes, J.C. Kappes, J.P. Moore, J.G. Sodroski, and H. Desaire. 2017. Glycosylation benchmark profile for HIV-1 Envelope glycoprotein production based on eleven env trimers. *J Virol* 91:

Go, E.P., D. Hua, and H. Desaire. 2014. Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. *J Proteome Res* 13:4012-4027.

Go, E.P., Y. Zhang, S. Menon, and H. Desaire. 2011. Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 DeltaCFI shows variability in the V1 and V2 regions. *J Proteome Res* 10:578-591.

Haynes, B.F., and J.R. Mascola. 2017. The quest for an antibody-based HIV vaccine. *Immunol Rev* 275:5-10.

Huang, J., B.H. Kang, M. Pancera, J.H. Lee, T. Tong, Y. Feng, H. Imamichi, I.S. Georgiev, G.Y. Chuang, A. Druz, N.A. Doria-Rose, L. Laub, K. Sliepen, M.J. van Gils, A.T. de la Pena, R. Derking, P.J. Klasse, S.A. Migueles, R.T. Baier, M. Alam, P. Pugach, B.F. Haynes, R.T. Wyatt, R.W. Sanders, J.M. Binley, A.B. Ward, J.R. Mascola, P.D. Kwong, and M. Connors. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. *Nature* 515:138-142.

This article is protected by copyright. All rights reserved
Joos, B., A. Trkola, H. Kuster, L. Aceto, M. Fischer, G. Stiegler, C. Armbruster, B. Vcelar, H. Katinger, and H.F. Gunthard. 2006. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). *Antimicrob Agents Chemother* 50:1773-1779.

Julien, J.P., A. Cupo, D. Sok, R.L. Stanfield, D. Lyumkis, M.C. Deller, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, A.B. Ward, and I.A. Wilson. 2013a. Crystal structure of a soluble cleaved HIV-1 envelope trimer. *Science* 342:1477-1483.

Julien, J.P., J.H. Lee, A. Cupo, C.D. Murin, R. Derking, S. Hoffenberg, M.J. Caulfield, C.R. King, A.J. Marozsan, P.J. Klasse, R.W. Sanders, J.P. Moore, I.A. Wilson, and A.B. Ward. 2013b. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. *Proc Natl Acad Sci U S A* 110:4351-4356.

Khayat, R., J.H. Lee, J.P. Julien, A. Cupo, P.J. Klasse, R.W. Sanders, J.P. Moore, I.A. Wilson, and A.B. Ward. 2013. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. *J Virol* 87:9865-9872.

Klasse, P.J., R.S. Depetris, R. Pejchal, J.P. Julien, R. Khayat, J.H. Lee, A.J. Marozsan, A. Cupo, N. Cocco, J. Korzun, A. Yasmeen, A.B. Ward, I.A. Wilson, R.W. Sanders, and J.P. Moore. 2013. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. *J Virol* 87:9873-9885.

Klasse, P.J., C.C. LaBranche, T.J. Ketas, G. Ozorowski, A. Cupo, P. Pugach, R.P. Ringe, M. Golabek, M.J. van Gils, M. Guttman, K.K. Lee, I.A. Wilson, S.T. Butera, A.B. Ward, D.C. Montefiori, R.W. Sanders, and J.P. Moore. 2016. Sequential and simultaneous immunization of rabbits with HIV-1 Envelope glycoprotein SOSIP.664 trimers from clades A, B and C. *PLoS Pathog* 12:e1005864.

Korber, B., P. Hraber, K. Wagh, and B.H. Hahn. 2017. Polyvalent vaccine approaches to combat HIV-1 diversity. *Immunol Rev* 275:230-244.
Lee, J.H., R. Andrabi, C.Y. Su, A. Yasmeen, J.P. Julien, L. Kong, N.C. Wu, R. McBride, D. Sok, M. Pauthner, C.A. Cottrell, T. Nieuwsma, C. Blattner, J.C. Paulson, P.J. Klasse, I.A. Wilson, D.R. Burton, and A.B. Ward. 2017. A broadly neutralizing antibody targets the dynamic HIV Envelope Trimer apex via a long, rigidified, and anionic beta-hairpin structure. *Immunity* 46:690-702.

Lee, J.H., D.P. Leaman, A.S. Kim, A. Torrents de la Pena, K. Sliepen, A. Yasmeen, R. Derking, A. Ramos, S.W. de Taeye, G. Ozorowski, F. Klein, D.R. Burton, M.C. Nussenzweig, P. Poignard, J.P. Moore, P.J. Klasse, R.W. Sanders, M.B. Zwick, I.A. Wilson, and A.B. Ward. 2015. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. *Nat Commun* 6:8167.

Lyumkis, D., J.P. Julien, N. de Val, A. Cupo, C.S. Potter, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, B. Carragher, I.A. Wilson, and A.B. Ward. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. *Science* 342:1484-1490.

Medina-Ramirez, M., F. Garces, A. Escolano, P. Skog, S.W. de Taeye, I. Del Moral-Sanchez, A.T. McGuire, A. Yasmeen, A.J. Behrens, G. Ozorowski, T. van den Kerkhof, N.T. Freund, P. Dosenovic, Y. Hua, A.D. Gitlin, A. Cupo, P. van der Woude, M. Golabek, K. Sliepen, T. Blane, N. Kootstra, M.J. van Breemen, L.K. Pritchard, R.L. Stanfield, M. Crispin, A.B. Ward, L. Stamatatos, P.J. Klasse, J.P. Moore, D. Nemazee, M.C. Nussenzweig, I.A. Wilson, and R.W. Sanders. 2017. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. *J Exp Med* 214:2573-2590.

Neville, D.C., R.A. Dwek, and T.D. Butters. 2009. Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. *J Proteome Res* 8:681-687.

Pancera, M., T. Zhou, A. Druz, I.S. Georgiev, C. Soto, J. Gorman, J. Huang, P. Acharya, G.Y. Chuang, G. Ofek, G.B. Stewart-Jones, J. Stuckey, R.T. Bailier, M.G. Joyce, M.K. Louder, N. Tumba, Y. Yang, B. Zhang, M.S. Cohen, B.F. Haynes, J.R. Mascola, L. Morris, J.B. Munro, S.C. Blanchard, W. Mothes, M. Connors, and P.D. Kwong. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. *Nature* 514:455-461.

This article is protected by copyright. All rights reserved
Pritchard, L.K., S. Vasiljevic, G. Ozorowski, G.E. Seabright, A. Cupo, R. Ringe, H.J. Kim, R.W. Sanders, K.J. Doores, D.R. Burton, I.A. Wilson, A.B. Ward, J.P. Moore, and M. Crispin. 2015. Structural constraints determine the glycosylation of HIV-1 Envelope trimers. Cell Rep 11:1604-1613.

Pugach, P., G. Ozorowski, A. Cupo, R. Ringe, A. Yasmeen, N. de Val, R. Derking, H.J. Kim, J. Korzun, M. Golabek, K. de Los Reyes, T.J. Ketas, J.P. Julien, D.R. Burton, I.A. Wilson, R.W. Sanders, P.J. Klasse, A.B. Ward, and J.P. Moore. 2015. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89:3380-3395.

Ringe, R.P., G. Ozorowski, K. Rantalainen, W.B. Struwe, K. Matthews, J.L. Torres, A. Yasmeen, C.A. Cottrell, T.J. Ketas, C.C. LaBranche, D.C. Montefiori, A. Cupo, M. Crispin, I.A. Wilson, A.B. Ward, R.W. Sanders, P.J. Klasse, and J.P. Moore. 2017a. Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers. J Virol 91:

Ringe, R.P., G. Ozorowski, A. Yasmeen, A. Cupo, V.M. Cruz Portillo, P. Pugach, M. Golabek, K. Rantalainen, L.G. Holden, C.A. Cottrell, I.A. Wilson, R.W. Sanders, A.B. Ward, P.J. Klasse, and J.P. Moore. 2017b. Improving the expression and purification of soluble, recombinant native-like HIV-1 Envelope glycoprotein trimers by targeted sequence changes. J Virol 91:

Ringe, R.P., A. Yasmeen, G. Ozorowski, E.P. Go, L.K. Pritchard, M. Guttman, T.A. Ketas, C.A. Cottrell, I.A. Wilson, R.W. Sanders, A. Cupo, M. Crispin, K.K. Lee, H. Desaire, A.B. Ward, P.J. Klasse, and J.P. Moore. 2015. Influences on the design and purification of soluble, recombinant native-like HIV-1 Envelope glycoprotein trimers. J Virol 89:12189-12210.

Safrit, J.T., P.E. Fast, L. Gieber, H. Kuipers, H.J. Dean, and W.C. Koff. 2016. Status of vaccine research and development of vaccines for HIV-1. Vaccine 34:2921-2925.

Sanders, R.W., R. Derking, A. Cupo, J.P. Julien, A. Yasmeen, N. de Val, H.J. Kim, C. Blattner, A.T. de la Pena, J. Korzun, M. Golabek, K. de Los Reyes, T.J. Ketas, M.J. van Gils, C.R. King, I.A. Wilson, A.B. Ward, P.J. Klasse, and J.P. Moore. 2013. A next-generation cleaved, soluble
HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. *PLoS Pathog* 9:e1003618.

Sanders, R.W., and J.P. Moore. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design. *Immunol Rev* 275:161-182.

Sanders, R.W., M.J. van Gils, R. Derking, D. Sok, T.J. Ketas, J.A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, H. Arendt, H.J. Kim, J.H. Lee, P. Pugach, M. Williams, G. Debnath, B. Moldt, M.J. van Breemen, G. Isik, M. Medina-Ramirez, J.W. Back, W.C. Koff, J.P. Julien, E.G. Rakasz, M.S. Seaman, M. Guttman, K.K. Lee, P.J. Klasse, C. LaBranche, W.R. Schief, I.A. Wilson, J. Overbaugh, D.R. Burton, A.B. Ward, D.C. Montefiori, H. Dean, and J.P. Moore. 2015. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. *Science* 349:aac4223.

Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D.R. Burton, F. Pereyra, D.D. Ho, B.D. Walker, M.S. Seaman, P.J. Bjorkman, B.T. Chait, and M.C. Nussenzweig. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* 333:1633-1637.

Stamatatos, L., M. Pancera, and A.T. McGuire. 2017. Germline-targeting immunogens. *Immunol Rev* 275:203-216.

Torrents de la Pena, A., J.P. Julien, S.W. de Taeye, F. Garces, M. Guttman, G. Ozorowski, L.K. Pritchard, A.J. Behrens, E.P. Go, J.A. Burger, E.E. Schermer, K. Sliepen, T.J. Ketas, P. Pugach, A. Yasmeen, C.A. Cottrell, J.L. Torres, C.D. Vavourakis, M.J. van Gils, C. LaBranche, D.C. Montefiori, H. Desaire, M. Crispin, P.J. Klasse, K.K. Lee, J.P. Moore, A.B. Ward, I.A. Wilson, and R.W. Sanders. 2017. Improving the immunogenicity of native-like HIV-1 Envelope trimers by hyperstabilization. *Cell Rep* 20:1805-1817.
Trkola, A., H. Kuster, P. Rusert, V. von Wyl, C. Leemann, R. Weber, G. Stiegler, H. Katinger, B. Joos, and H.F. Gunthard. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. *J Virol* 82:1591-1599.

Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J.P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I. *J Virol* 70:1100-1108.

Verkerke, H.P., J.A. Williams, M. Guttman, C.A. Simonich, Y. Liang, M. Filipavicius, S.L. Hu, J. Overbaugh, and K.K. Lee. 2016. Epitope-independent purification of native-like Envelope trimers from diverse HIV-1 isolates. *J Virol* 90:9471-9482.

Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, J.L. Mitcham, P.W. Hammond, O.A. Olsen, P. Phung, S. Fling, C.H. Wong, S. Phogat, T. Wrin, M.D. Simek, G.P.I. Protocol, W.C. Koff, I.A. Wilson, D.R. Burton, and P. Poignard. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature* 477:466-470.

Wang, Z., C. Lorin, M. Koutsoukos, D. Franco, B. Bayat, Y. Zhang, A. Carfi, S.W. Barnett, and F. Porter. 2016. Comprehensive characterization of reference standard lots of HIV-1 subtype C gp120 oroteins for clinical trials in southern African regions. *Vaccines (Basel)* 4:

Ward, A.B., and I.A. Wilson. 2017. The HIV-1 envelope glycoprotein structure: nailing down a moving target. *Immunol Rev* 275:21-32.

Wieczorek, L., S.J. Krebs, V. Kalyanaraman, S. Whitney, S. Tovanabutra, C.G. Moscoso, E. Sanders-Buell, C. Williams, B. Slike, S. Molnar, V. Dussupt, S.M. Alam, A.L. Chenine, T. Tong, E.L. Hill, H.X. Liao, M. Hoelscher, L. Maboko, S. Zolla-Pazner, B.F. Haynes, M. Pensiero, F. McCutchan, S. Malek-Salehi, R.H. Cheng, M.L. Robb, T. VanCott, N.L. Michael, M.A. Marovich, C.R. Alving, G.R. Matyas, M. Rao, and V.R. Polonis. 2015. Comparable antigenicity and
immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 Envelope for use in preclinical and clinical vaccine research. *J Virol* 89:7478-7493.

Yasmeen, A., R. Ringe, R. Derking, A. Cupo, J.P. Julien, D.R. Burton, A.B. Ward, I.A. Wilson, R.W. Sanders, J.P. Moore, and P.J. Klasse. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. *Retrovirology* 11:41.

Yu, B., D.P. Fonseca, S.M. O'Rourke, and P.W. Berman. 2010. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. *J Virol* 84:1513-1526.

Zambonelli, C., A.K. Dey, S. Hilt, S. Stephenson, E.P. Go, D.F. Clark, M. Wininger, C. Labranche, D. Montefiori, H.X. Liao, R.I. Swanstrom, H. Desaire, B.F. Haynes, A. Carfi, and S.W. Barnett. 2016. Generation and characterization of a bivalent HIV-1 subtype C gp120 protein boost for proof-of-concept HIV vaccine efficacy trials in southern Africa. *PLoS One* 11:e0157391.
Figure Legends

Figure 1. Overview of the process used to purify BG505 SOSIP.664 trimers. Schematic of the 10 steps involved in the purification of the trimer fraction from the initial gp140 protein harvest. The four dedicated viral clearance/inactivation steps are highlighted by an *. MM-AEX, Mixed mode anion exchange.

Figure 2. NS-EM images of BG505 SOSIP.664 trimer Drug Substance products from small (50 L) and large (200 L) scale production runs. (A) 50 L Confirmation Run; (B) 200 L Demonstration Run; (C) 200 L cGMP Run. All three runs yielded trimers that were 100% native-like.

Figure 3. Properties of BG505 SOSIP.664 trimers purified from the Demonstration Run. (A) CD profile of BG505 SOSIP.664 trimer, (B) DSC profile of BG505 SOSIP.664 trimer showing a Tonset of 59.4°C and Tm of 66.6°C.

Figure 4. N-linked glycosylation analysis. (A) Total glycan profiling of glycans enzymatically released from BG505 SOSIP.664 gp140 (200 L Demonstration Run), fluorescently labelled and analyzed by HILIC-UPLC. Oligomannose-type and hybrid glycans (green) were identified by their sensitivity to Endo H digestion. Peaks containing complex-type glycans are colored in pink. The pie charts summarize the quantification of the peak areas. (B) Percentage quantification of the oligomannose-type series Man5GlcNAc2 to Man9GlcNAc2 (M5 to M9) of the glycan profiles shown in A. (C) Glycan sequencing of glycan profile shown in A. Peaks were assigned by a sequential enzymatic digestion of 2-AA labelled glycans with a panel of exoglycosidases, followed by HILIC-UPLC analysis. The top panel shows the undigested glycan profile of BG505.
SOSIP.664 trimers produced in CHO cells. The profiles below represent digestions with the following exoglycosidases: Neuraminidase from *Clostridium perfringens*, α-L-fucosidase from bovine kidney, β1, 4-galactosidase from *Streptococcus pneumoniae*, β-N-acetylglucosaminidase from *S. pneumoniae* and Jack bean α-mannosidase. (D) Quantitative site-specific N-glycosylation of 23 of the 28 sites on BG505 Env. The glycoprotein was digested with trypsin, chymotrypsin, pronase, and GluC, and then analyzed by LC-ESI MS. Glycans are categorized as oligomannose series (M5 to M9), hybrids (H), and fucosylated hybrids (FH), and also by the number of branching antennae (A) of complex type glycans. An, number (n) of antennae; Gn, number (n) of galactose residues; F, presence of a core fucose (Behrens et al., 2016). The bar graphs represent the means of two analytical replicates, and the quantification of oligomannose-type (green) and complex/hybrid-type glycans (pink) on the individual sites is summarized in the pie charts.

**Figure 5. SPR analysis of bNAb binding to BG505 SOSIP.664 trimers.** The binding of BG505 SOSIP.664 trimer in solution to the indicated immobilized bNAbs (3BNC117, 2G12, PGT130, PG9, PGT145, PGT151, 35022 and 3BC315) was analyzed by SPR. The green curves of the sensorgram show one of two replicate profiles of the specific response for each NAb (see SOM Methods) during 300s of association and 600s of dissociation. Note that the y-axis scales are adjusted according to the maximum binding to each bNAb. The red dotted lines correspond to 0 response units (RU) on the y-axis.
Table Legends

Table 1. Properties of the four top CHO cell sub-clones expressing BG505 SOSIP.664 gp140. The sub-clones were generated via the GPEX® method. The unpurified trimer concentrations in the supernatants were estimated using the PGT145-ELISA. Maximum cell density was measured on day 10. The pre-specified criteria for viable cell density post-thaw and cell viability post thaw were >5 x 10⁶ cells/vial and >85%, respectively. All four sub-clones passed pre-specified criteria for Bioburden, Mycoplasma content and Retroviral vector component content and the appropriate insert size.

Table 2. Stability study on MCB sub-clone 270-4. Unpurified trimer concentrations in supernatants were estimated using the PGT145-ELISA. SD, standard deviation. Gene copy numbers were measured by qPCR and % viability by microscopic counting of viable cells.

Table 3. Comparison of small (50 L) and large (200 L) scale production runs used to produce the BG505 SOSIP.664 trimer Drug Substance. Attributes of the Drug Substance are listed together with the outcomes of the 50 L Confirmation and 200 L Demonstration runs (both non-cGMP), and the 200 L cGMP run. ND, Not determined; LOQ, Limit of quantitation; EU, Endotoxin units; CFU, Colony forming units.

Table 4. Viral clearance/inactivation achieved during the process for purifying BG505 SOSIP.664 trimers. The viral load reduction (recorded as log₁₀ compared to baseline) of XMuLV and/or MMV achieved by the four viral clearance/inactivation steps that are marked by an * in the overall purification process in Fig. 2. DO, Dissolved oxygen.
Table 5. Forced Degradation study. (A) Summary of chemical and physical degradation stresses applied to purified BG505 SOSIP.664 trimers. (B) Outcome of the stress tests as evaluated by physical appearance, solution pH, protein content (A280), PGT145-binding (BLI), RP-HPLC, SE-HPLC and NS-EM. Data indicative of degradation events are highlighted in bold.
Supplementary Online Material

Supplementary Methods

Blue native polyacrylamide gel electrophoresis (BN-PAGE)

Purified BG505 SOSIP.664 trimers (or fractions derived from SEC column runs) were analyzed on BN-PAGE gels (Invitrogen), which were stained with Coomassie blue to visualize protein bands (Chung et al., 2014; Sanders et al., 2013).

Detecting BG505 SOSIP.664 trimers by ELISA

The ELISA to quantify trimer production during CHO cell line development and cell culture process development was adapted from one described previously (Chung et al., 2014). Briefly, Env proteins were captured to the solid phase via bNAb 2G12 (Trkola et al., 1996), and trimers were detected using biotin-labeled PGT145, a bNAb to a quaternary (i.e., trimer-dependent) Env epitope (Lee et al., 2017). We also used biotin-labeled MAb F105 to probe for the production of undesired forms of Env, as the CD4-binding site (CD4bs) epitope for this non-neutralizing antibody (non-NAb) is inaccessible on native trimers but available on gp120 monomers and uncleaved gp140s (Chung et al., 2014; Sanders et al., 2013; Yasmeen et al., 2014). MAb 2G12 was purchased from Polymun Inc., and MAbs PGT145 and F105 were provided by IAVI.

For biotin conjugation, we used an EZ-Link Micro Sulfo-NHS-Biotinylation Kit (Thermo Scientific). PGT145 or F105 (200 µg) was passed through a Zebra™ Spin desalting column and incubated with Sulfo-NHS-Biotin solution (11 mM) for 1 h at room temperature. The mixture was passed through a desalting column to remove excess biotin. The collected flow-through solution contains biotinylated MAb (bio-PGT145 or bio-F105) and was stored at 4°C.
Trimer production in culture supernatants from CHO cell lines was assessed as follows. Briefly, Maxisorp ELISA plates were coated with 2G12 at 1 µg/mL overnight at 4°C (100 µL/well). The wells were washed three times with PBS containing 0.05% Tween 20 (PBST), and then blocked with PBS containing 2% non-fat milk for 1 h at room temperature. Culture supernatants were serially diluted and added to the wells for 2 h at room temperature. After three washes with PBST, 100 µl of bio-PGT145 or bio-F105 (1 µg/mL) was added for 1 h, before washing three times with PBST and addition of poly-HRP streptavidin (Thermo Scientific; 1:2500 dilution in PBS containing 2% non-fat milk and 10% sheep serum) for a further 1 h. After a final three washes in PBST, the colorimetric endpoint was generated using the 1-STEP Ultra TMB-ELISA substrate (Thermo Scientific) and measured at 450 nm.

**Detecting BG505 SOSIP.664 trimers by Biolayer Interferometry (BLI)**

This assay, based on the same bNAb as the PGT145-ELISA, was designed during the process development procedure to improve throughput and intra-assay precision. It was used during the three production runs. Before the cGMP run, the BLI assay was qualified and used for Drug Substance and Drug Product release and for stability testing. The assay was carried out using an Octet QK384 instrument (Pall Fortebio). The baseline (control) Protein A biosensor was dipped in sample wells for 60 s at 1000 rpm, and the PGT145 MAb (1 µg/mL) was then captured by the Protein A biosensors for 300 s at 1000 rpm. The BG505 SOSIP.664 trimers in test samples (110 µL/well) were allowed to bind to PGT145 during the association step (300 s at 1000 rpm). The biosensor hydration step took 600 s, the plate temperature was set to 30°C and the sensor offset was 4 mm. Standard curves were produced using a reference stock of BG505 SOSIP.664 trimers of known concentration to estimate the trimer content of test samples.
Reverse phase ultra-performance liquid chromatography (RP-UPLC)

A Waters Acquity UPLC Protein BEH C4 300 A, 2.1 x 150 mm column was used. Samples were injected at a 6 µg column load with UV detection at 214 nm. The auto sampler temperature was set to 10°C and the column temperature to 25°C. The run was conducted at a flow rate of 0.2 mL/min. with a run time of 50 min. The mobile phase gradient was 1 % Mobile Phase B per min.

Size exclusion high performance liquid chromatography (SE-HPLC)

Samples were injected into a Tosoh TSKgel SW Aggregate, 3 µm, 7.8 mm x 30 cm column at a 15 µg column load with UV detection at 220 nm. The column was maintained at ambient temperature. The run was conducted at a flow rate of 0.5 mL/min with a run time of 30 min.

Protein concentration by A280

Protein concentration was determined using UV/Vis Spectroscopy and the extinction coefficient of 1.59 AU*mL/mg*cm that was derived experimentally using amino acid analysis. There is a 2.1% difference between this experimental value and the theoretical value of 1.56 AU*mL/mg*cm. This method was used to quantify trimers from all of the production runs. Note that it does not take into account the glycan content of the trimers; to do so requires multiplying the peptidic mass by ~1.7.

Amino acid analysis

This method was used to determine the overall primary sequence composition of BG505 SOSIP.664 trimers (3 mg/mL, Demonstration Run), and hence the experimental extinction coefficient for converting A280 absorbance measurements into protein concentrations. A standard vapor phase acid hydrolysis was conducted and the hydrolyzed peptide samples were analyzed using RP-HPLC. Samples were first dialyzed into PBS to avoid any interference with the hydrolysis/analysis methods. Hydrolysis was carried out in triplicate by incubation of a known
molar amount of a control protein (bovine serum albumin, BSA) or the BG505 SOSIP.664 trimer (10 μL) with 989 μL of constant boiling 6 N hydrochloric acid, a few crystals of phenol, and 1 μL of beta-mercaptoethanol for 18-24 h at 110°C. The samples were then dried by centrifugal evaporation and reconstituted in 400 μL of sample diluent and analyzed by RP-HPLC. Asparagine and glutamine are converted to aspartic acid and glutamic acid, respectively, during vapor phase hydrolysis and, hence, these two pairs of amino acids were quantified together. Because the peptide bonds between hydrophobic amino acids, such as valine, isoleucine, and leucine, are often difficult to break during vapor phase hydrolysis, recoveries of these amino acids were lower than average. Similarly, serine, threonine, tyrosine and methionine are often partially destroyed and showed poor recoveries. Tryptophan and cysteine are completely destroyed during standard hydrolysis conditions and, hence, were ignored in amino acid analyses.

The percentage recoveries of each amino acid ranged from 85.7% to 123.7%, with the exception of methionine and cysteine, for which the values were 55.0% and 1.8%, respectively. Tryptophan was excluded from the analysis as it was completely degraded during vapor phase hydrolysis. The overall average percentage recovery was 94.5% (Table S2). However, because of their poor recoveries, methionine and cysteine were excluded from the final calculation, which yielded an overall recovery average of 103.3%. An experimental extinction coefficient of 1.59 AU*mL/mg*cm was then calculated, a value that differs from the theoretical value of 1.56 AU*mL/mg*cm by 2.1%. The experimental value was used for all protein determinations.

**Circular dichroism (CD)**

The secondary structure composition of the purified BG505 SOSIP.664 trimer (3 mg/mL, Demonstration Run) was analyzed by measuring the differential absorbance of left- and right-circularly polarized light by far-UV and near-UV CD, using a Jasco J-810 Spectropolarimeter.
Far-UV analysis was performed using a quartz cylindrical cell with 0.1 mm path length, near-UV via a rectangular quartz cuvette with 10 mm path length.

**Differential scanning calorimetry (DSC)**

Data on the BG505 SOSIP.664 trimer (3 mg/mL, Demonstration Run) were collected from a single thermal denaturation curve that was derived by heating the sample from 25°C to 90°C at a scan rate of 90°C per h (Sanders et al., 2013; Sanders et al., 2015).

**Negative-stain electron microscopy (NS-EM) imaging**

Purified trimers (from all production runs) were prepared for NS-EM analysis by adsorbing 3 μL of sample (~0.02 mg/mL) onto a glow discharged, carbon-coated copper 400 mesh grid. Following blotting, the samples were stained using either 2% (w/v) uranyl formate (3 μL of stain for 60 s) or Nano-W (NanoProbes, Inc.; 3 μL of stain for 7 s, followed by blotting and a second 3 μL of stain for 15 s). Data collection, processing, and particle analysis methods have been previously described (Khayat et al., 2013; Sanders et al., 2013; Sanders et al., 2015).

**Surface Plasmon Resonance (SPR)**

The binding of purified BG505 SOSIP.664 trimers (3 mg/mL, Demonstration Run) to immobilized MAbs was analyzed by at 25°C on a BIAcore 3000 instrument (GE Healthcare) by one of several methods described previously (Yasmeen et al., 2014). Briefly, affinity-purified mouse anti-human IgG Fc (GE Healthcare Biosciences, USA) at 50 μg/ml in sodium acetate (pH 5.0) was amine-coupled to dextran, reaching immobilization levels of ~10,000 RU (response units). The bNAbs were added at 1 μg/ml in-running buffer (150 mM NaCl, 10 mM HEPES, pH 7.4, 3 mM EDTA plus 0.005% Surfactant P20) to three channels on each C1 chip, at a flow rate of 5 μL/min, and captured to give R_L values of 340 ± 2.8 RU; the channel with only anti-Fc was used as a negative control. The trimers at 10 nM in running buffer were injected at a flow rate of 50 μL/min.
Association was recorded for 300 s and dissociation for 600 s. The background signal (2.8 ± 1.2 % of the total signal) in the control channel was subtracted to give the specific resonance (in RU).

The anti-IgG-Fc surface was regenerated after each cycle by a single injection of 10 mM glycine (pH 2.0) for 120 s at a flow rate of 30 µL/min. Note that this SPR format with solution-phase trimers at a single concentration does not allow kinetic modeling and is influenced by differing stoichiometries and valencies (Yasmeen et al., 2014).

The sources of the bNAb used in the SPR analysis were as follows: PGT145 (Lee et al., 2017), PGT151 (Blattner et al., 2014), PG9 (Julien et al., 2013b) and PGT130 (Walker et al., 2011) were obtained from IAVI; 2G12 (Trkola et al., 1996) was purchased from Polymun Scientific; 3BNC117 (Scheid et al., 2011) was donated by Michel Nussenzweig, 35O22 was a gift from Mark Connors (Huang et al., 2014) and 3BC315 was provided by Andrew Ward (Lee et al., 2015).

N-glycosylation analysis

Quantitative, site-specific N-glycosylation analysis was performed essentially as described elsewhere (Behrens et al., 2016). BG505 SOSIP.664 trimers (3 mg/mL, Demonstration Run) were processed on reducing and non-reducing SDS-PAGE gels to resolve the gp120 plus gp41 and gp140 components, respectively. The separated bands were digested, within the gels, with PNGase F to release the N-linked glycans, which were fluorescently labeled with 2-aminobenzoic acid (2-AA), analyzed and quantified by hydrophilic interaction chromatography-ultra-performance liquid chromatography (HILIC-UPLC) (Neville et al., 2009; Pritchard et al., 2015). Briefly, the total pool of released glycans was fractionated by ion mobility electrospray MS using a Waters Synapt G2Si instrument (Waters Corp.). Glycopeptides were analyzed by LC-ESI MS using a Q-Exactive Orbitrap (Thermo Fisher).
Disulfide bond analysis

The disulfide bonding profile of the BG505 SOSIP.664 trimer (3 mg/mL, Demonstration Run) was mapped using MS (Ringe et al., 2015; Torrents de la Pena et al., 2017). Briefly, ~20 µg of protein was alkylated in the dark for 1 h with a 10-fold excess of 4-vinylpyridine. The alkylated protein was then deglycosylated with PNGase F in 100 mM ammonium citrate buffer (pH 6.5) for one week at 37°C, then digested with trypsin at a 30:1 ratio (protein to enzyme) overnight at 37°C. About 5 µL (1 µg protein digest) was analyzed by liquid chromatography MS (LC-MS) using an Orbitrap Velos Pro™ hybrid (Thermo Scientific, San Jose CA) mass spectrometer equipped with an electron transfer dissociation (ETD) module coupled to an Acquity Ultra Performance Liquid Chromatography (UPLC®) system (Waters, Milford MA). The peptides were separated on a C18 PepMap™ 300 column (300 µm i.d. x 15 cm, 300 Å; Thermo Scientific, Sunnyvale, CA) using a linear gradient starting from 3% B to 40% B in 50 min, then to 90% B in 10 min, and re-equilibration at 97% A for 10 min. Solvent A was 99.9% HPLC-grade H₂O + 0.1% formic acid, solvent B was 99.9 % HPLC grade acetonitrile + 0.1% formic acid, and the flow rate was 5 µL per minute. Collision induced dissociation (CID) and ETD data were collected in data-dependent scans, and peptides containing free cysteine residues were sought using the Mascot search engine. Disulfide bond patterns were analyzed manually as described previously (Go et al., 2014).

Methods used in the Forced Degradation studies

Vials of purified BG505 SOSIP.664 trimer (3 mg/mL, Demonstration Run), formulated in DS/DP buffer, were treated as summarized below. The test samples were analyzed for physical appearance, pH, protein content by ultraviolet absorbance (A280), PGT145-BLI, SDS-PAGE, RP-UPLC and SE-HPLC assays in reference to a control (untreated) sample.

Heat stress: One vial of the trimer was placed in a 50°C incubator for one week.
Freeze-thaw stress: Three vials of the trimer were placed in a freezer at -75 ± 10°C for at least 2 h, and then thawed at RT for at least 2 h. This cycle was carried out 3 times. Since there were no visible signs of aggregation/degradation after the third cycle, the samples from the first two were not tested.

Agitation: Four vials were used in total. Two were placed upright on an orbital shaker at 250 rpm at RT, while two were kept static in close proximity to serve as controls. One test and one control vial were removed after 24 h of agitation, the second pair after 48 h, and stored at -75°C for later testing.

Oxidation: Two µL of 30% hydrogen peroxide was added to one vial of trimer (final concentration, 0.04% H₂O₂) and sample was then incubated for 4 h at 37°C.

Deamidation/Base hydrolysis: Sufficient of a 1 M Tris solution was added to one vial of trimer until the pH reached 8.9, and the sample was then incubated for 3 days at 40°C.

Acid hydrolysis: Sufficient of a 1 N HCl solution was added to one vial of trimer until the pH fell to 3.6, and the sample was then incubated for 3 days at 40°C.

Photostability: Two vials of trimer were placed in a photostability chamber at 5 ± 3°C, with one vial wrapped in aluminum foil to serve as the control and the other left unwrapped. The samples were exposed to light to an extent sufficient to meet the ICH (International Conference on Harmonization) Q1B guidelines (1.2 million lux hours of cool, white light and 200 watt hours per square meter of UV energy). Accordingly, the samples were exposed to 8 kilolux of cool, white light for 150 h, and then to 10 watt hours per square meter of UV light for 20 h.
Supplementary Results

Forced Degradation study

This study was intended to identify degradation pathways for BG505 SOSIP.664 trimers and assess whether potential degradation products could be detected. The purified trimers, formulated in vials at 2 mg/mL in 20 mM Tris, 100 mM NaCl, pH 7.5, were evaluated for their responses to agitation, heat stress, freeze-thaw cycles, light stress (photostability), oxidation and exposure to low or high pH conditions. To detect stress-induced changes in the trimers, we used assays based on physical appearance, solution pH, protein content (UV A280), PGT145-reactivity (BLI) and chromatography profile (RP-UPLC and SE-HPLC). In addition, we used NS-EM to measure the percentage of trimers that remained in native-like form.

The purified trimers were stable under all test conditions except when oxidized with 0.04% H₂O₂ or when exposed to a low pH (3.5) solution (Table 5). Adverse effects of oxidation were detectable by measuring PGT145-binding by BLI (Table 5) or by RP-UPLC, but not by SE-HPLC or NS-EM (Fig. S3). The data imply that the oxidized proteins were still trimeric, but that the PGT145 epitope at the trimer apex had been damaged. Low pH (3.5) treatment, i.e., acid hydrolysis, caused catastrophic trimer disintegration into protomeric forms (e.g., monomers and dimers), as judged by PGT145-binding (Table 5), NS-EM, SE-HPLC and, to a lesser extent, RP-UPLC (Fig. S4). The trimers were not detectably affected by physical agitation (up to 48 h at RT), heat-stress (50°C for up to 1 week), exposure to light or freeze-thaw cycles, and there was no deamidation of asparagine residues after exposure to a high pH solution (Table 5).
Supplementary Figures

Figure S1. Cell culture (i.e., upstream) process for BG505 SOSIP.664 gp140 production using GPEx® CHO stable cell clone 270-4. Schematic of the design of the seed train expansion for the 200 L scale Demonstration Run and the final 200 L cGMP Run using the 50 L Wave Bioreactor and then the 200 L XDR Single-Use Bioreactor (SUB).

Figure S2. Polyacrylamide gel electrophoretic analysis of BG505 SOSIP.664 trimers (A) BN-PAGE. Lane 1, Molecular Weight Marker; Lane 2, trimers purified from 200L Demonstration Run; Lane 3, trimers purified from 50L Confirmation Run. (B) SDS-PAGE under non-reducing (Lanes 1 and 3) or reducing (Lanes 2 and 4) conditions. Lanes 1 and 2, trimers purified from 50L Confirmation Run; Lanes 3 and 4, trimers purified from 200L Demonstration Run. Lane 5, Molecular weight markers.

Figure S3. Oxidation of BG505 SOSIP.664 trimers. Purified BG505.SOSIP.664 trimers were treated with 0.04% H₂O₂, as part of the Forced Degradation study. The effect of oxidation was assessed by (A) RP-HPLC, (B) SE-HPLC, (C) NS-EM.

Figure S4. Acid treatment of BG505 SOSIP.664 trimers. The stability of purified BG505 SOSIP.664 trimers was assessed following treatment with low pH (i.e., 3.5), as part of the Forced Degradation study, to highlight its susceptibility to acidic conditions. The outcome was assessed by (A) RP-HPLC, (B) SE-HPLC, (C) NS-EM.
Supplementary Table Legends

Table S1. Process parameters used to produce BG505 SOSIP.664 trimers during the Demonstration Run and the cGMP Run. (A) For the 50 L Wave Bioreactor. (B) For the 200 L XDR Single-Use Bioreactor (SUB). A schematic of the overall process is shown in Fig. S1.

Table S2. Amino acid analysis. The percentages of the experimentally detected over theoretical values for the amino acids in BG505 SOSIP.664 trimers are shown as molar ratios.

Table S3. Disulfide bonds present in BG505 SOSIP.664 trimers. (A) Canonical disulfide bonds: the disulfide-linked peptides were characterized by LC-MS. The identity of each peptide was confirmed by high-resolution MS data and MS/MS analysis. (B) Aberrant disulfide bonds: the disulfide-linked peptides were characterized by LC-MS. The identity of each peptide was confirmed by high-resolution MS data and MS/MS analysis. The two aberrant peptides were detected in trace amounts, as observed previously (Go et al., 2015).

Table S4. Excipient screening study. The listed buffers and pH conditions were screened, with or without added excipient (150 mM L-arginine or 250 mM sucrose), in trimer stability and formulation studies. RH, Relative humidity.
### Table 1.

| Sub-clone | Trimer production (mg/L) | Maximum cell density (viable cells/mL) | Viable cell density post-thaw (cells/ml) | Cell viability post-thaw (%) | Gene copy index |
|-----------|--------------------------|----------------------------------------|------------------------------------------|------------------------------|-----------------|
| 232-4     | 229                      | 29.0 x 10⁵                             | 13.08 x 10⁶                             | 86                           | 4.48            |
| 270-4     | 205                      | 37.5 x 10⁵                             | 14.94 x 10⁶                             | 92                           | 5.99            |
| 327-9     | 118                      | 74.7 x 10⁵                             | 22.00 x 10⁶                             | 98                           | 5.54            |
| 397-3     | 76                       | 62.1 x 10⁵                             | 15.50 x 10⁶                             | 96                           | 4.53            |
Table 2.

| Generation | Trimer concentration (mean ± SD, mg/L) | Gene copy index (mean ± SD) | Cell viability (%) |
|------------|----------------------------------------|-----------------------------|-------------------|
| 0          | 85 ± 1                                 | 5.71 ± 0.33                 | 96.4              |
| 8          | 119 ± 26                               | 5.68 ± 0.27                 | 93.1              |
| 17         | 117 ± 4                                | 5.55 ± 0.29                 | 93.7              |
| 28         | 121 ± 11                               | 5.54 ± 0.37                 | 97.8              |
| 35         | 165 ± 23                               | 5.94 ± 0.21                 | 97.7              |
| 42         | 101 ± 20                               | 5.61 ± 0.22                 | 99.2              |
| Attributes                                      | Confirmation Run (50L) | Demonstration Run (200L) | cGMP Run (200L) |
|------------------------------------------------|------------------------|--------------------------|-----------------|
| Concentration                                  | 13.5 mg/mL             | 2.8 mg/mL                | 3.0 mg/mL       |
| Identity                                       | Positive               | Positive                 | Positive        |
| Percent trimer (PGT145 BLI)                    | ND                     | 121%                     | 92%             |
| Percent trimer (SEC)                           | 100%                   | 96.4%                    | 96%             |
| Purity (RP-HPLC)                               | 94.9%                  | 90%                      | 93.4%           |
| Percent cleavage                               | Comparable to reference | Comparable to reference | Comparable to reference |
| Residual host cell protein                     | 5 ppm                  | 6 ppm                    | 3 ng/mg         |
| Residual DNA                                   | <LOQ (15 ppb)          | <LOQ (10 ppb)            | <LOQ (2 pg/mg)  |
| Residual 2G12 MAb                              | <LOQ (0.6 ppm)         | <LOQ (8 ppm)             | <17 ng/mg       |
| Residual Protein A                             | <LOQ (0.05 ppm)        | <LOQ (0.2 ppm)           | <0.3 ng/mg      |
| Endotoxin                                      | ND                     | 0.0398 EU/mL             | 0.02 EU/mL      |
| Bioburden                                      | ND                     | 0 CFU/10mL               | 0 CFU/10mL      |
| pH                                             | 7.5                    | 7.5                      | 7.5             |
| Appearance                                     | Clear, colorless solution | Clear, colorless solution | Clear, colorless solution |
Table 4.

| Purification process steps                          | Log_{10} virus reduction |
|-----------------------------------------------------|--------------------------|
|                                                     | XMuLV        | MMV          |
| 2G12 MAb immuno-affinity column                     | ≥5.08         | 1.07         |
| Detergent (Triton X-100, 0.5%) Inactivation         | 5.96          | N/A          |
| Capto Adhere (MM-AEX) column                        | 3.35          | ≥6.26        |
| Viral filtration (Planova 20N)                      | ≥5.23         | ≥5.00        |
| Total                                               | ≥19.62        | ≥12.33       |
Table 5.

(A)

| Sample              | Condition                                                                 |
|---------------------|---------------------------------------------------------------------------|
| General control     | Stored at -75 ± 10°C                                                      |
| Agitation           | Orbital shaking at 200-300 rpm for 24 and 48 h                            |
| Agitation control   | Samples stored at room temperature for 24 and 48 h, without agitation    |
| Oxidation           | Exposed to 0.04% H$_2$O$_2$ at 37°C for 4 h                              |
| Heat stress         | Incubated at 50°C for 1 week                                             |
| Freeze and thaw     | Three cycles of freezing at -75°C for at least 2 h followed by thawing at room temperature |
| Acid hydrolysis     | pH 3.6 at 40°C for 3 days                                                |
| Base deamidation    | pH 8.9 at 40°C for 3 days                                                |
| Photostability      | 8.00 kilolux of cool white light for 150 h followed by 10.00 W/square meter UV light for 20 h |
| Photostability control | Sample double wrapped with aluminum foil incubated in photostability chamber under same conditions |

(B)

| Conditions          | Appearance        | pH   | Protein (mg/mL) | PGT145 binding (%) | RP-HPLC (% in main peak) | SE-HPLC (% in trimer peak) | NS-EM Trimer (%) |
|---------------------|-------------------|------|-----------------|---------------------|--------------------------|---------------------------|-----------------|
| General control     | Clear, Colorless  | 7.5  | 1.9             | 100                 | 92.7                     | 96.0                      | 100             |
| Agitation 24h       | Clear, Colorless  | 7.5  | 2.0             | 104                 | 92.4                     | 95.8                      | 100             |
| Agitation 24h control | Clear, Colorless | 7.5  | 2.0             | 85                  | 92.9                     | 96.1                      | 100             |
| Agitation 48h       | Clear, Colorless  | 7.5  | 1.9             | 99                  | 92.4                     | 96.2                      | 100             |
| Agitation 48h control | Clear, Colorless | 7.5  | 2.0             | 87                  | 92.7                     | 95.8                      | 100             |
| Oxidation           | Clear, Colorless  | 7.5  | 2.0             | 22                  | 5.5                      | 94.7                      | 100             |
| Heat stress         | Clear, Colorless  | 7.5  | 1.9             | 84                  | 89.7                     | 94.9                      | 100             |
| Freeze thaw cycles  | Clear, Colorless  | 7.5  | 2.0             | 83                  | 92.7                     | 95.2                      | >90             |
| Acid hydrolysis     | Clear, Colorless  | 7.5  | 2.0             | 14                  | 79.9                     | 33.6                      | 0               |
| Base deamidation    | Clear, Colorless  | 7.5  | 1.9             | 71                  | 90.5                     | 96.6                      | 100             |
| Photostability      | Clear, Colorless  | 7.5  | 2.0             | 84                  | 91.6                     | 96.0                      | 100             |
| Photostability control | Clear, Colorless  | 7.5  | 2.0             | 86                  | 92.7                     | 96.1                      | 100             |
Figure 1.

| Process | Description |
|---------|-------------|
| 2G12 MAb-affinity | Affinity column, positive selection |
| UF/DF | Concentration to support detergent inactivation |
| Detergent (Triton X-100) Treatment | Viral inactivation |
| Amberlite adsorption | Triton X-100 removal |
| Protein A | 2G12 MAb-removal, flow-through |
| Capto Adhere | MM-AEX Column, negative selection |
| Viral filtration | Plasmavir (50k) filtration |
| UF/DF | Concentration to support SE-HPLC |
| SE-HPLC | Isolation of trimeric gp140 |
| UF/DF | Final concentration and buffer exchange |
| Sterile Filtration | 0.22μm filtration for sterile Drug Product |
Figure 3.

(A)

Tm: 66.6°C
Tm(peak): 59.4°C
Tm(DS): 5.1°C

[Graph showing a peak with labels for Tm, Tm(peak), and Tm(DS).]
Figure 4.

|     | M5 | M6 | M7 | M8 | M9 | sum |
|-----|----|----|----|----|----|-----|
| gp140 | 15 | 4  | 8  | 13 | 30 | 88  |
| gp120 | 15 | 4  | 8  | 14 | 35 | 73  |
| gp41  | 14 | 4  | 4  | 3  | 1  | 26  |
Figure 4.

(B) gp140

Neuraminidase
- *

Fucosidase
- ♦

Galactosidase
- ♦

N-Acetylglucosaminidase
- □

Mannosidase
- ■
Figure 4. (D)

N88
N133
N137
N156
N160
N190
N197
N234
N262
N276
N295
N332
N339
N355
N363
N386
N392
N448
N462
N611
N618
N625
N637
Figure 5.